San Diego gene-sequencing giant Illumina said Monday that its board approved the spinoff of early cancer-detecting startup Grail. The move brings the local biotechnology company one step closer to ...

Illumina received a bullish rating upgrade from JPMorgan, which raised its recommendation to Overweight from Neutral and lifted its December 2026 price target to $185 from $125, citing growing ...

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country. It’s part ...

Illumina (ILMN) stock gains as J.P. Morgan upgrades the company to Overweight, lifting its 2026 price target to $185 based on ...

(NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and ...

llumina on Thursday forecast core business revenue to be nearly flat in the coming year compared to 2023 amid subdued demand for its genetic testing tools and diagnostics products. The San Diego-based ...

Illumina exhibits better profitability ratios than many of its peers, which indicates that the company could continue to invest in its operations. In Q3 2025, ILMN raised its EPS to $4.65-$4.75, ...

The collaboration connects IDT’s sequencing library preparation tools with Illumina’s DRAGEN analysis platform to improve ...

Bulls argue that Illumina is the better gene sequencing stock because in some sequencing markets, it's basically the only option in town, particularly in the all-important market for next generation ...

BIOS/UEFI vulnerabilities in the iSeq 100 DNA sequencer from U.S. biotechnology company Illumina could let attackers disable devices used for detecting illnesses and developing vaccines. The Illumina ...

In May and June 2026, Integrated DNA Technologies announced a collaboration with Illumina to connect IDT’s xGen FFPE and cfDNA library prep workflows with Illumina’s DRAGEN secondary analysis platform ...

Illumina’s announced partnerships with IBM’s Watson and Philips help shore up the firm's data-analysis capabilities and clinical diagnostic marketing efforts, respectively, but the announcement of a ...